HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Verve Therapeutics (NASDAQ:VERV) and maintained a price target of $15.
August 12, 2024 | 9:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Verve Therapeutics and maintained a price target of $15.
The reiteration of a Buy rating and maintenance of a $15 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100